BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
UBS
Moodys
Express Scripts
US Department of Justice
Cipla
Mallinckrodt
Deloitte
Teva
Citi

Generated: January 19, 2018

DrugPatentWatch Database Preview

Bimatoprost - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for bimatoprost and what is the scope of bimatoprost freedom to operate?

Bimatoprost
is the generic ingredient in three branded drugs marketed by Apotex Inc, Lupin Ltd, Sandoz Inc, and Allergan, and is included in eight NDAs. There are twenty-three patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Bimatoprost has sixty-four patent family members in twenty-one countries.

There are twelve drug master file entries for bimatoprost. Five suppliers are listed for this compound. There are three tentative approvals for this compound.
Summary for bimatoprost
Pharmacology for bimatoprost
Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog
Medical Subject Heading (MeSH) Categories for bimatoprost
Tentative approvals for BIMATOPROST
Applicant Application No. Strength Dosage Form
➤ Subscribe➤ Subscribe0.03SOLUTION; OPHTHALMIC
➤ Subscribe➤ Subscribe0.01%SOLUTION; OPHTHALMIC
➤ Subscribe➤ Subscribe0.01%SOLUTION;OPHTHALMIC

US Patents and Regulatory Information for bimatoprost

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lupin Ltd BIMATOPROST bimatoprost SOLUTION/DROPS;OPHTHALMIC 203991-001 Feb 20, 2015 AT RX No Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for bimatoprost

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 ➤ Subscribe ➤ Subscribe
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for bimatoprost

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,388,029 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins ➤ Subscribe
7,351,404 Method of enhancing hair growth ➤ Subscribe
8,926,953 Method of enhancing hair growth ➤ Subscribe
8,298,518 Method of enhancing hair growth ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for bimatoprost

Supplementary Protection Certificates for bimatoprost

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00099 Netherlands ➤ Subscribe PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
C/GB02/035 United Kingdom ➤ Subscribe PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
C0033 France ➤ Subscribe PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Covington
Queensland Health
Moodys
Argus Health
UBS
Cerilliant
Julphar
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot